Palmatine Ameliorates MASLD in Type 2 Diabetes
Researchers published in Scientific Reports (2026) report preclinical evidence that palmatine ameliorates MASLD in type 2 diabetes by modulating hepatic apoptosis and inflammation. Using integrated bioinformatics and single-cell analyses, they identified 138 overlapping targets refined to 43 genes and five core proteins, and validated effects in a four-week high-fat diet and streptozotocin rat model. Palmatine improved metabolic markers, reduced inflammatory cytokines, and lessened hepatic steatosis dose-dependently.
Scoring Rationale
Peer-reviewed, bioinformatics-backed preclinical findings with dose-dependent effects; limited by rodent model and need for human clinical validation.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
